ATE415421T1 - Deamidiertes interferon-beta - Google Patents

Deamidiertes interferon-beta

Info

Publication number
ATE415421T1
ATE415421T1 AT05818235T AT05818235T ATE415421T1 AT E415421 T1 ATE415421 T1 AT E415421T1 AT 05818235 T AT05818235 T AT 05818235T AT 05818235 T AT05818235 T AT 05818235T AT E415421 T1 ATE415421 T1 AT E415421T1
Authority
AT
Austria
Prior art keywords
deamidated
beta
interferon
interferon beta
native
Prior art date
Application number
AT05818235T
Other languages
English (en)
Inventor
Kenji Furuya
Deborah Johnson-Jackson
Diana Ruscio
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE415421T1 publication Critical patent/ATE415421T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
AT05818235T 2004-11-10 2005-11-10 Deamidiertes interferon-beta ATE415421T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62683704P 2004-11-10 2004-11-10

Publications (1)

Publication Number Publication Date
ATE415421T1 true ATE415421T1 (de) 2008-12-15

Family

ID=36337216

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05818235T ATE415421T1 (de) 2004-11-10 2005-11-10 Deamidiertes interferon-beta

Country Status (16)

Country Link
US (2) US7595040B2 (de)
EP (1) EP1809662B1 (de)
JP (1) JP4891250B2 (de)
KR (1) KR101330626B1 (de)
CN (1) CN101056890B (de)
AT (1) ATE415421T1 (de)
AU (1) AU2005304486B2 (de)
BR (1) BRPI0517697A (de)
CA (1) CA2587061C (de)
DE (1) DE602005011321D1 (de)
ES (1) ES2318575T3 (de)
MX (1) MX2007004990A (de)
PL (1) PL1809662T3 (de)
PT (1) PT1809662E (de)
RU (1) RU2404190C2 (de)
WO (1) WO2006053134A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
WO2008020968A2 (en) * 2006-08-08 2008-02-21 Novartis Ag Recombinant interferon-beta with enhanced biological activity
JP2010525821A (ja) 2007-05-02 2010-07-29 アンブルックス，インコーポレイテッド 修飾ＩＦＮβポリペプチドおよびこれらの使用
US8273561B2 (en) * 2007-10-05 2012-09-25 Nuron Biotech, Inc. High pressure treatment of aggregated interferons
EP3126379B1 (de) * 2014-04-04 2019-05-22 Ares Trading SA Neuartige ifn-beta-proteinanaloga
RU2739261C1 (ru) * 2019-12-31 2020-12-22 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ количественного определения антипролиферативной активности интерферона-бета человека

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
ES2224290T5 (es) 1996-12-24 2012-03-12 Biogen Idec Ma Inc. Formulaciones l�?quidas estables de interferón.
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
KR100826621B1 (ko) * 1997-09-23 2008-05-02 렌트슐러 비오테히놀로기 게엠베하 액상 인터페론-베타 제제
JP2003508028A (ja) 1999-07-28 2003-03-04 ジェネンテック・インコーポレーテッド 腫瘍治療のための組成物と方法
ES2180416B1 (es) 2001-03-12 2004-06-01 BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen.
AR034749A1 (es) * 2001-07-09 2004-03-17 Schering Ag Formulaciones de interferon beta humano
KR100541850B1 (ko) 2003-03-31 2006-01-11 삼성정밀화학 주식회사 인간 인터페론-베타 변이체 및 그의 제조방법

Also Published As

Publication number Publication date
WO2006053134A3 (en) 2006-08-31
ES2318575T3 (es) 2009-05-01
JP2008519769A (ja) 2008-06-12
JP4891250B2 (ja) 2012-03-07
CA2587061C (en) 2011-08-16
WO2006053134A2 (en) 2006-05-18
BRPI0517697A (pt) 2008-10-14
AU2005304486A1 (en) 2006-05-18
RU2404190C2 (ru) 2010-11-20
CN101056890A (zh) 2007-10-17
CA2587061A1 (en) 2006-05-18
US20060120998A1 (en) 2006-06-08
KR101330626B1 (ko) 2013-11-18
US7595040B2 (en) 2009-09-29
EP1809662B1 (de) 2008-11-26
EP1809662A2 (de) 2007-07-25
RU2007121515A (ru) 2008-12-20
PL1809662T3 (pl) 2009-07-31
DE602005011321D1 (de) 2009-01-08
KR20070084559A (ko) 2007-08-24
US20090263355A1 (en) 2009-10-22
MX2007004990A (es) 2007-06-14
CN101056890B (zh) 2012-05-09
AU2005304486B2 (en) 2011-08-11
PT1809662E (pt) 2009-02-26

Similar Documents

Publication Publication Date Title
NO2017027I2 (no) efmoroctocog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet.
ATE415421T1 (de) Deamidiertes interferon-beta
WO2003104270A3 (en) GENES OF DUDULINE 2, EXPRESSION PRODUCTS, NON-HUMAN ANIMAL MODEL: USES IN HUMAN HEMATOLOGICAL DISEASES
DE60042122D1 (de) Fibroblasten wachstumsfaktor-ähnliche polypeptide
BRPI0514790A (pt) muteìna de fgf-21 de humano, ou um seu peptìdeo biologicamente ativo, método para produzir a muteìna, composição farmacêutica, e, uso da muteìna de fgf-21 de humano
ATE388963T1 (de) Homogene herstellungen von il-29
NZ754961A (en) Growth differentiation factor 15 (gdf-15) constructs
MX2007009466A (es) Anticuerpos monoclonales de anti-interferon alfa y metodos para su uso.
BRPI0516455A (pt) fitase de citrobacter freundii e homólogos
BRPI0416683A (pt) muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21
ATE417595T1 (de) Keratin-bindende polypeptide
DE68929043T2 (de) Für androgen-rezeptor-protein kodierende dna
DE60125381D1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
EP1773867A4 (de) Proteinartige verbindungen und anwendungen davon
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
MX2021007434A (es) Peptidos de colageno producidos de forma sintetica y recombinante con eficacia biologica.
BRPI0414793A (pt) uso do fator anti-secretor
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
Guo et al. Molecular cloning and characterization of a novel bovine IFN-ε
Hauck et al. Effects of synthesized elastin peptides on human leukocytes.
Ketscher et al. ISG15 uncut: Dissecting enzymatic and non-enzymatic functions of USP18 in vivo
ATE482272T1 (de) Zytokinproteinfamilie
MX2009007248A (es) Peptidos bio-activos cortos para modulacion celular e inmunologica.
MX2009001348A (es) Interferon-beta recombinante con actividad biologica mejorada.
Andersen et al. Peginterferon lambda-1a, a new therapeutic for hepatitis C infection, from bench to clinic

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1809662

Country of ref document: EP